Three essential amino acids that share a structural quirk, bypass the liver, and burn directly in muscle. Meet leucine, isoleucine, and valine — the BCAAs.
The most abundant amino acid in muscle protein. Triggers the mTOR switch for protein synthesis. Discovered 1820 from cheese.
Read full story →Structural isomer of leucine with two chiral centers. Four possible mirror-image forms — life uses only one. Discovered 1904.
Read full story →The smallest BCAA. One misplaced valine causes sickle cell disease. Named after valerian root, discovered by Emil Fischer in 1901.
Read full story →The name refers to their side chains: instead of a straight carbon chain, each has a branch — an extra carbon arm extending from the beta carbon. Leucine and isoleucine are isomers (same formula, C₆H₁₃NO₂, different arrangement), while valine is one carbon shorter. The branching creates a compact, rigid, nonpolar structure that resists breakdown and packs tightly into the hydrophobic cores of folded proteins.
This structural similarity comes with a shared metabolic fate. Unlike virtually all other amino acids, which are processed primarily in the liver, BCAAs skip hepatic metabolism almost entirely. They pass through the liver essentially unchanged and are taken up and metabolized in peripheral tissues — primarily skeletal muscle, but also the heart, kidney, and brain. This makes BCAAs the only amino acids that muscle can use directly as a fuel source without liver involvement.
The liver lacks high activity of branched-chain amino acid transaminase — the first enzyme needed to begin BCAA catabolism. So BCAAs sail through hepatic circulation and arrive at muscle essentially intact. Muscle tissue has high transaminase activity and can process them efficiently. This is one of the most unusual features of amino acid metabolism — the majority rule (liver first) just doesn't apply here.
Among the three BCAAs, leucine plays a unique signaling role that goes beyond simple nutrition. Leucine is the primary activator of mTORC1 — the mechanistic Target of Rapamycin Complex 1 — a protein kinase that acts as the master switch for cellular protein synthesis. When leucine concentrations rise after a meal, mTORC1 is activated, ribosomes spin up, and protein synthesis rates increase.
This means leucine doesn't just provide building material for new proteins — it sends the signal that building should begin. The other two BCAAs contribute energy and carbon skeletons, but leucine uniquely carries information. It's the reason that the leucine content of a meal, not just total protein, strongly predicts how well it stimulates muscle protein synthesis.
All three BCAAs share a common degradation pathway. The first two steps — transamination and oxidative decarboxylation — are handled by enzymes that act on all three simultaneously. The second enzyme, branched-chain alpha-keto acid dehydrogenase (BCKDH), is the critical chokepoint.
In maple syrup urine disease (MSUD), BCKDH is defective. All three BCAAs and their keto-acid derivatives accumulate to toxic levels in blood and urine. The disease takes its name from the distinctive sweet, maple-syrup odor that appears in the urine of affected newborns — caused by the accumulated keto-acids. Untreated, the amino acid buildup causes neurological damage within days of birth. It's a rare but vivid demonstration of how essential normal BCAA metabolism is to brain function.
| Property | Leucine (L) | Isoleucine (I) | Valine (V) |
|---|---|---|---|
| Mol. weight | 131.18 g/mol | 131.18 g/mol | 117.15 g/mol |
| Chiral centers | 1 | 2 | 1 |
| Codons | 6 (most of any AA) | 3 | 4 |
| Metabolism | Purely ketogenic | Both glucogenic & ketogenic | Purely glucogenic |
| mTOR activation | Strong (primary trigger) | Moderate | Weak |
| Discovery | 1820 (Braconnot) | 1904 (Ehrlich) | 1901 (Fischer) |
| Famous for | Leucine zipper, mTOR | Two chiral centers | Sickle cell mutation |
BCAA supplements became popular in sports nutrition in the 1980s, based on research showing that BCAAs are oxidized in muscle during prolonged exercise. The hypothesis was that supplementing BCAAs during training would spare muscle protein breakdown and improve performance. The evidence has turned out to be more nuanced: BCAAs alone stimulate protein synthesis less effectively than complete proteins, and the benefit of isolated BCAA supplementation over adequate dietary protein is modest for most people.
The more interesting nutritional insight is about food quality: because leucine is the primary mTOR trigger, the leucine content of a protein source matters alongside total protein amount. Whey protein — derived from milk — is particularly high in leucine (~11% by weight), which helps explain why it's frequently studied in the context of muscle protein synthesis. Leucine thresholds of around 2–3 grams per meal appear to be needed for maximal mTOR activation.